Questions about the BEST-Fluids trial - Authors' reply

Affiliations

¹ Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA 5000, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia. Electronic address: michael.collins@sa.gov.au.
² Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia; Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia.
³ Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia; Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; Translational Research Institute, Brisbane, QLD, Australia.
⁴ Department of Renal Medicine, Kidney Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

Comment

Michael G Collins et al. Lancet. 2024.

. 2024 Mar 9;403(10430):911-912.

doi: 10.1016/S0140-6736(23)02680-6.

¹ Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA 5000, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia. Electronic address: michael.collins@sa.gov.au.
² Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia; Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia.
³ Australasian Kidney Trials Network, Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia; Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; Translational Research Institute, Brisbane, QLD, Australia.
⁴ Department of Renal Medicine, Kidney Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.

No abstract available

Comment on

Questions about the BEST-Fluids trial.
Canet E, Zafrani L. Canet E, et al. Lancet. 2024 Mar 9;403(10430):908-909. doi: 10.1016/S0140-6736(23)02681-8. Lancet. 2024. PMID: 38460984 No abstract available.
Questions about the BEST-Fluids trial.
Masset C, Chapelet A, Dumont R, Ville S, Garandeau C, Houzet A, Kervella D, Dantal J, Blancho G, Cantarovich D, Giral M, Figueres L; Nantes DIVAT Consortium. Masset C, et al. Lancet. 2024 Mar 9;403(10430):909-910. doi: 10.1016/S0140-6736(23)02682-X. Lancet. 2024. PMID: 38460985 No abstract available.
Questions about the BEST-Fluids trial.
Gueret G, Laffon M. Gueret G, et al. Lancet. 2024 Mar 9;403(10430):910. doi: 10.1016/S0140-6736(23)02683-1. Lancet. 2024. PMID: 38460986 No abstract available.
Questions about the BEST-Fluids trial.
Verney C, Dreyfuss D, Gaudry S. Verney C, et al. Lancet. 2024 Mar 9;403(10430):911. doi: 10.1016/S0140-6736(23)02684-3. Lancet. 2024. PMID: 38460987 No abstract available.